Opendata, web and dolomites

ENDFLU SIGNED

Evaluation of ratioNally Designed Influenza vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDFLU project word cloud

Explore the words cloud of the ENDFLU project. It provides you a very rough idea of what is the project "ENDFLU" about.

demonstration    indian    induces    world    safety    protective    fueled    infection    biochemical    influenza    clade    create    rationally    constructs    pandemic    dose    expressed    compliant    adoption    protein    cell    gmp    vaccine    elicit    formulation    scientific    combat    surface    na    either    candidates    advocacy    cross    plan    immunogenicity    combination    chim    trial    optimal    followed    enter    manufacturing    functional    designed    mva    human    assessing    ferrets    mediated    immunity    epitopes    complementary    h5    construct    efficacy    select    model    seeds    polyepitope    broadly    india    endflu    repository    nanoparticles    clinical    artificial    conserved    manifestations    optimize    toward    vaccination    combined    proteins    criteria    head    optimized    m2e    rational    expertise    mice    achievements    stem    biophysical    fusions    worldwide    hemagglutinin    strategies    clinically    internal    generation    ing    humoral    encode    encoding   

Project "ENDFLU" data sheet

The following table provides information about the project.

Coordinator
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER 

Organization address
address: BUNTEWEG 2
city: HANNOVER
postcode: 30559
website: www.tiho-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 14˙444˙867 €
 EC max contribution 8˙646˙254 € (60%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙234˙225.00
2    CURVE CLINICAL BV NL (AMSTERDAM DUIVENDRECHT) participant 3˙364˙571.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 2˙342˙075.00
4    VIB BE (ZWIJNAARDE - GENT) participant 608˙750.00
5    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 435˙707.00
6    LUNDS UNIVERSITET SE (LUND) participant 360˙925.00
7    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 300˙000.00
8    COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH IN (NEW DEHLI) participant 0.00
9    INDIAN INSTITUTE OF SCIENCE IN (BANGALORE) participant 0.00
10    INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM IN (THIRUVANANTHAPURAM) participant 0.00
11    MANIPAL ACADEMY OF HIGHER EDUCATION IN (MANIPAL) participant 0.00
12    MYNVAX PRIVATE LIMITED IN (BANGLADORE) participant 0.00
13    SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY IN (MUMBAI) participant 0.00
14    TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE IN (FARIDABAD) participant 0.00

Map

 Project objective

ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDFLU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDFLU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

HEAP (2020)

Human Exposome Assessment Platform

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More